- Title
- Role of oxidative stress in the pathology and management of human tuberculosis
- Creator
- Shastri, Madhur D.; Shukla, Shakti Dhar; Chong, Wai Chin; Dua, Kamal; Peterson, Gregory M.; Patel, Rahul P.; Hansbro, Philip M.; Eri, Rajaraman; O'Toole, Ronan F.
- Relation
- Oxidative Medicine and Cellular Longevity Vol. 2018
- Publisher Link
- http://dx.doi.org/10.1155/2018/7695364
- Publisher
- Hindawi
- Resource Type
- journal article
- Date
- 2018
- Description
- Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is the leading cause of mortality worldwide due to a single infectious agent. The pathogen spreads primarily via aerosols and especially infects the alveolar macrophages in the lungs. The lung has evolved various biological mechanisms, including oxidative stress (OS) responses, to counteract TB infection. M. tuberculosis infection triggers the generation of reactive oxygen species by host phagocytic cells (primarily macrophages). The development of resistance to commonly prescribed antibiotics poses a challenge to treat TB; this commonly manifests as multidrug resistant tuberculosis (MDR-TB). OS and antioxidant defense mechanisms play key roles during TB infection and treatment. For instance, several established first-/second-line antitubercle antibiotics are administered in an inactive form and subsequently transformed into their active form by components of the OS responses of both host (nitric oxide, S-oxidation) and pathogen (catalase/peroxidase enzyme, EthA). Additionally, M. tuberculosis has developed mechanisms to survive high OS burden in the host, including the increased bacterial NADH/NAD+ ratio and enhanced intracellular survival (Eis) protein, peroxiredoxin, superoxide dismutases, and catalases. Here, we review the interplay between lung OS and its effects on both activation of antitubercle antibiotics and the strategies employed by M. tuberculosis that are essential for survival of both drug-susceptible and drug-resistant bacterial subtypes. We then outline potential new therapies that are based on combining standard antitubercular antibiotics with adjuvant agents that could limit the ability of M. tuberculosis to counter the host’s OS response.
- Subject
- TB; Mycobacterium tuberculosis; phagocytic cells; macrophage
- Identifier
- http://hdl.handle.net/1959.13/1402023
- Identifier
- uon:34998
- Identifier
- ISSN:1942-0900
- Rights
- Copyright © 2018 Madhur D. Shastri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Language
- eng
- Full Text
- Reviewed
- Hits: 4776
- Visitors: 5414
- Downloads: 386
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 1 MB | Adobe Acrobat PDF | View Details Download |